Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011

Blood

Volumn 124, Issue 23, 2014, Pages 3389-3397

  Collins, Peter W ^a   Palmer, Benedict P ^b   Chalmers, Elizabeth A ^c   Hart, Daniel P ^d   Liesner, Ri ^e   Rangarajan, Savita ^f   Talks, Katherine ^g   Williams, Michael ^h   Hay, Charles R M ⁱ  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b National Haemophilia Database   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g ROYAL VICTORIA INFIRMARY   (United Kingdom)

^h BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; RECOMBINANT FACTOR VIII SQ;

ANTAGONISTS AND INHIBITORS; ANTIBODY PRODUCTION; BLOOD; CHILD; COHORT ANALYSIS; HEMOPHILIA A; HUMAN; IMMUNOLOGY; INCIDENCE; INFANT; NEWBORN; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; UNITED KINGDOM;

ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FACTOR VIII; GREAT BRITAIN; HEMOPHILIA A; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; ISOANTIBODIES; SEVERITY OF ILLNESS INDEX;

EID: 84914142516     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-580498     Document Type: Article

References (18)

1. Gouw SC, van der Bom JG, Ljung R, et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3):231-239.
2. van der Bom JG, Gouw SC, Rosendaal FR. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A. Haemophilia. 2014;20(2): e171-e174.
3. Iorio A, Skinner MW, Makris M. Factor VIII products and inhibitors in severe hemophilia A. 2013;368:1456.
4. Kessler CM, Iorio A. The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. Haemophilia. 2013;19(3):351-354.
5. Moorehead P. Statistical modelling in the RODIN study. Haemophilia. 2014;20(4):e351-e352.
6. Giangrande PLF; KOGENATE Bayer Study Group. Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia. 2002;8(Suppl 2):19-22.
7. Kreuz W, Gill JC, Rothschild C, et al; International Kogenate-FS Study Group. Full-length sucroseformulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost. 2005;93(3):457-467.
8. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia. 2006;12(Suppl 6):15-22.
9. Collins PW, Chalmers E, Hart DP, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol. 2013;160(2):153-170.
10. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006;133(6): 591-605.
11. Recht M, Nemes L, Matysiak M, et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: Demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. 2009;15:869-880.
12. Franchini M, Coppola A, Rocino A, et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: A 2013 update. 2013;39:752-766.
13. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost. 2010; 8(6):1256-1265.
14. Fischer K, Lewandowski D, Marijke van den Berg H, Janssen MP. Validity of assessing inhibitor development in haemophilia PUPs using registry data: The EUHASS project. 2012;18:e241-e246.
15. Chalmers EA, Brown SA, Keeling D, et al; Paediatric Working Party of UKHCDO. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia. 2007;13(2):149-155.
16. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4648-4654.
17. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost. 2007;5(7): 1383-1390.
18. Calvez T, Chambost H, Claeyssens-Donadel S, d'Orien R, Goulet V, Guillet B, Heritier V, Milien V, Rothschild C, Roussel-Robert V, Vinciguerra C, Goudemand J. and for the FranceCoagNetwork. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A [published online ahead of print September 24, 2014]. Blood.